Transferred from: Medicilon

The tide is turbulent, time is like weaving, and the "progress bar" of history never stops. 2024 is a new year for Medicilon in its international journey, a key year for deepening and strengthening its own strength, and a year for shining in the coexistence of challenges and opportunities. This year, Medicilon's "progress bar" also continued to load.

In 2024, we will explore the deep needs of existing R&D, and also explore more possibilities of new tracks and technologies; We are committed to the upgrading and improvement of our service platform and innovative technologies, and we are also keen to share valuable experience and insights. We continue to strengthen team building and deepen customer connections to jointly promote the development and evolution of both parties...... Unswervingly implement the development strategy and constantly refresh the "progress bar" of development

This year, Medicilon closely followed the R&D trend and continued to inject innovative vitality into the one-stop biomedical preclinical R&D service platform

Powerful tools for drug discovery: continuous application of "click chemistry" to promote drug discovery, construction of small molecule drug synthase library, etc.;

Overcoming "undruggable": establishing a variety of new target drug R&D, screening and detection platforms, such as: KRAS, PTPN2, etc.;

Targeted protein degradation: Refining the PROTAC & molecular glue platform, such as researching new molecular glues, overcoming PROTAC drug resistance, etc.;

ADC deep cultivation and acceleration: develop new Linkers, build Linker high-throughput synthesis platform, and continue to explore conjugation processes.

Sound antibody storage: humanized antibody modification (e.g., Nectin-4, etc.), construction of high-expression cell lines, etc.;

Process development and re-optimization: Assist in the process development and research of multiple drugs, such as: aprexitentan, sparsentan, and high-end generic drugs of inflammation series and cardiovascular series;

Upgrading of preparation services: Build a number of high-end preparation R&D technology platforms, such as: improved inhalation preparation new drug R&D platform, macromolecule nebulized inhalation preparation R&D platform, etc.;

Re-innovation of pharmacokinetic technology: the establishment of bioanalytical technology based on exosome drugs or carriers, the application of ultracentrifugation to determine plasma protein binding, etc.;

Challenging the problem of drug resistance: developing drug resistance models for anti-tumor drugs with multiple targets, such as CDK4/6, PARP, etc.;

Enabling new drug research: We will continue to build in vitro and in vivo efficacy evaluation models for PDXO and PDXOC for various cancer types, efficacy evaluation models for ophthalmic diseases, and develop new models to meet clinical needs.

In 2024, Medicilon's globalization strategy will be further deepened, and the second R&D center in Boston will be officially put into operation, equipped with cutting-edge instruments and animal laboratories, relying on a rich animal model library, it can provide services such as pharmacodynamic evaluation of small molecule chemical drugs and biological drugs, as well as pharmacokinetic evaluation and optimization in line with international standards, and the progress bar of the globalization strategy continues to move forward.

This year, Medicilon's cooperation network progress bar is continuing to expand outward, cooperating with Sapu Bioscience, Hengrui Pharmaceutical, Innonew Force, Binhui Biotech, etc., covering ADC, CGT, oncolytic virus, nucleic acid drugs, protein drugs, cell and gene therapy and other fields, and co-promoting the research and development of anti-tumor drugs with Hetuo Chuangzhan and Global Cancer Hospital, so as to jointly build a new ecology of pharmaceutical R&D.

In this year, Medicilon Analysis and Testing Center obtained the CNAS qualification certificate, and the test report was recognized by international authority; Successfully passed the ABSL-2 filing, becoming the first enterprise in Shanghai to have a non-human primate ABSL-2 laboratory, enabling AAV virus research.

In addition, Medicilon has earned the highest praise for its performance in several professional fields: it was rated "Excellent" in the 2024 Proficiency Testing Program for Toxicity Pathological Morphology Examination (NIFDC-PT-478) organized by the China Institute for Food and Drug Control, "Satisfactory" in the 2024 (3rd) Experimental Pathology Diagnostic Interlaboratory Comparison Activity, and "Satisfactory" in the proficiency test of Toxicity Pathology Examination (PT0031-2415) of the China National Accreditation Service for Conformity Assessment”； It was rated as "satisfactory" in the proficiency test of AAV genomic titer determination organized and implemented by the China Institute for Food and Drug Control.

This year, Medicilon successfully won the deep trust of the market and customers with its excellent technical service efficiency and quality, and won the 2024 VBEF "Best Customer Satisfaction Pharmaceutical CRO" Award, Insilico Medicine 2024 "Team Excellence Award", Qilu Ruige "2024 Best Team Award", Jingye Pharma "Best Cooperation Award", and Anrui Biotech "Excellent Service Award". Every honor is an affirmation of Medicilon's service and a driving force for Medicilon to continue to forge ahead.

This year, Medicilon's market expansion progress bar continued to accelerate, and through the combination of online and offline, it delivered innovative technologies in an all-round and multi-angle manner. In China, Medicilon has participated in 28 industry conferences and exhibitions, including the 9th E-Trade Bio-Industry Conference of BIOCHINA2024, the first Chinese Biomedical Science and Technology Association (CBA) China Annual Meeting in 2024, and CMC Industry Expo. Overseas, Medicilon has participated in 45 industry conferences and exhibitions, including the Society of Toxicology (SOT) 2024, American Association for Cancer Research (AACR) 2024, and BIO International Convention 2024, and has conducted in-depth negotiations with global pharmaceutical companies and scientific research institutions to continuously expand market boundaries and enhance the brand's international influence.

At the same time, Medicilon Cloud Lecture Hall has launched 34 online live courses, focusing on popular fields such as nucleic acid, XDC, liposomes, CAR-T cell therapy, cyclic peptide drugs, synthetic biology and CMC development, helping pharmaceutical colleagues overcome the core problems and challenges in various fields, answering various puzzles in R&D practice, and jointly promoting the progress and development of the industry.

In 2025, Medicilon is increasing R&D investment, deepening technological innovation, and iterating service platforms with a more high-spirited attitude to drive the sustainable development and industrial upgrading of the pharmaceutical industry. Medicilon's progress bar is moving towards a better future, constantly refreshing, and surpassing!

Recommended service platform

Preview of the live stream

About Medicilon

Medicilon (stock code: 688202.HK) Founded in 2004 and headquartered in Shanghai, SH is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and researchers. Medicilon's one-stop comprehensive service helps customers accelerate the process of new drug development with strong project management and more efficient and cost-effective R&D services, covering the whole process of pharmaceutical preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research. By the end of 2024, Medicilon has provided drug R&D services to more than 2,000 customers around the world, and has participated in the research and development of about 520 IND clinical trials of new drugs and generic drugs, growing together with high-quality customers at home and abroad. Medicilon will continue to be based on a global vision, focus on China's innovation, and contribute to human health!

(Redirected from: Medicilon).